188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas

Study ID
NCT01126463

Study type
Interventional

Study phase
Phase 1

Study status
Completed

Trial Acronym

LIP-RE-I

Trial Summary

This study is to determine the maximum tolerated dose and the recommended 188Re-SSS Lipiodol activity for hepatic intra-arterial injection in patients with hepato-cellular carcinoma. The new radioactive isotope 188Rhenium associated with Lipiodol is expected to reduce the radioprotection constraints and hence the duration of the hospitalisation in a protected room from 8 to 1 day.

More informations

Trial Starting Date

May 26,2010

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit